US$3.4m grant for Staph. aureus vaccine development
GlycoVaxyn has received a US$3.4m NIH grant to develop a novel Staphylococcus aureus vaccine
GlycoVaxyn AG, a developer of innovative bioconjugate vaccines, and professor Jean Lee, principal investigator at the Channing Laboratory, Brigham and Women’s Hospital, Harvard Medical School, have announced they have received a US$ 3.4 m NIH grant to finance preclinical development of a novel Staphylococcus aureus vaccine.
Using GlycoVaxyn’s proprietary technology, staphylococcal surface polysaccharides will be conjugated in vivo to conserved protein antigens from S. aureus. The efficacy of this novel bioconjugate vaccine will then be evaluated in different animal models of S. aureus infection.
‘GlycoVaxyn’s first generation S. aureus bioconjugate vaccine has shown protective efficacy in preclinical studies. The new generation vaccine is expected to give broader protection against a variety of S. aureus strains,’ said Dr Jean Lee.
GlycoVaxyn and the Brigham and Women’s Hospital have a long standing collaboration on this project, and the NIH funding will accelerate the development of potential vaccine candidates.
In parallel to this innovative approach, GlycoVaxyn, which started Phase I clinical trials with a bioconjugate vaccine against Shigella dysenteriae early this year, is expecting to start a clinical trial with its first generation S. aureus vaccine by late 2011.
‘Our bioconjugation technology allows us a very flexible and powerful approach to multivalent vaccine development, coupling polysaccharide to protein antigens in a strictly controlled way,’ said Dr Michael Wacker, cso and founder of GlycoVaxyn. ‘This grant confirms the potential of this approach and will allow extensive preclinical evaluation of the novel vaccine.’
Nosocomial infections, often caused by S. aureus, are a major concern in hospital settings accounting for estimated USD 5 billion in additional costs.
A conjugate vaccine, used to immunise against serious bacterial infections, is created by linking a sugar antigen to a carrier protein molecule. The current process to obtain such a structure is often very complex, unreliable and expensive. GlycoVaxyn’s S. aureus vaccine consists of capsular polysaccharide type 5 or 8 of S. aureus conjugated to a staphylococcal protein carrier. It is produced using GlycoVaxyn’s novel technology that allows the synthesis of these complex immunogenic bioconjugates via a biological process in E. coli, which makes the production more effective and controlled.